Clinical trials: NETs
Osteoporosis
A Study on Vertebral Bone Strength by Micro-CT-Like Image
In this study, we use conditional generation adversarial network to enhance the resolution of MSCT images and obtain micro-CT-like images.
- Trial name
- NCT04954417
- Testing
- Radiological scanning, Deep learning, Bio-mechanical testing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver…
- Conditions
- Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases
- Trial name
- NELMAS (NCT05987176)
- Testing
- Lutathera
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Neuroendocrine Tumors
Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor
The purpose of this study is to compare streptozotocin (STZ) vs everolimus as first line treatment for advanced pNET and to elucidate which sequence of STZ based chemotherapy and the mammalian Target of Rapamycin (mTOR)…
- Trial name
- SEQTOR (NCT02246127)
- Testing
- Drug: Everolimus, STZ-5FU
- Where
- 37 sites in Denmark, France and 6 more
- Volunteers
- 141 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT
the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT treatment and evaluate the response for treatment using PET/CT with different tracers
- Trial name
- NCT04622631
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Dr. Nayruz Knaana
Gastroenteropancreatic Neuroendocrine Tumors
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
The purpose of this study is to determine if 68Gallium-octreotate and 18Fluorodesoxyglucose uptake, apparent diffusion coefficient and post 177Lu-octreotate SPECT/CT dosimetry are reliable predictors for lesion-by-lesion…
- Trial name
- LUMEN (NCT01842165)
- Testing
- Intravenous injection of 177Lu-octreotate
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- Jules Bordet Institute
Gastroenteropancreatic Neuroendocrine Tumors
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors.
- Trial name
- NCT07165886
- Testing
- Sirolimus for injection (albumin bound), Octreotide long-acting injection, Everolimus
- Where
- China
- Volunteers
- 298 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Gastric Neoplasms, Pancreatic Neoplasms
Chromogranin A as Blood Marker in Cancer Patients
Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs.
- Conditions
- Gastric Neoplasms, Pancreatic Neoplasms, Small Intestinal Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03817866
- Testing
- BRAHMS CgA II KRYPTOR
- Where
- 4 sites in United States, Germany
- Volunteers
- 175 people
- Sponsor
- Brahms AG
Malaria, Anaemia
Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition
Although the risk of malaria is greatest in early childhood, significant numbers of schoolchildren remain at risk from malaria infection, clinical illness and death.
- Trial name
- NCT01454752
- Testing
- Intermittent parasite clearance
- Where
- Senegal
- Volunteers
- 860 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Neuroendocrine Tumors, Quality of Life
HRQoL During PRRT in Patients With NETs
Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which may affect the patients' health-related quality of life (HRQoL).
- Conditions
- Neuroendocrine Tumors, Quality of Life, Peptide Receptor Radionuclide Therapy
- Trial name
- NCT05427032
- Volunteers
- 756 people
- Sponsor
- Uppsala University
Neuroendocrine Tumors, Neoplasms
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug…
- Conditions
- Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
- Trial name
- NCT02943733
- Testing
- TAS-102, Temozolomide, Filgrastim
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Neuroendocrine Tumors
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4)…
- Trial name
- NCT05249114
- Testing
- Cabozantinib, Lu-177
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Gastro-entero-pancreatic Neuroendocrine Tumor
SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs
The research aims to prospectively include patients with GEP-NENs, undergo preoperative imaging assessment (including PET/CT and contrast-enhanced CT), and accurately delineate lymph node regions.
- Trial name
- NCT06344832
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Neuroendocrine Tumors, Carcinoid Tumor of GI System
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
Primary Objective: To assess how an amino acid based medical food (Enterade®) helps maintain the intestine's ability to absorb and retain fluids, leading to a reduction in diarrhea due to Neuroendocrine Tumors (NET) and/or…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumor of GI System, Diarrhea, Carcinoid Syndrome
- Trial name
- NCT03722511
- Testing
- Amino Acid Based Medical Food/Drink
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lowell Anthony, MD
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Well Differentiated Pancreatic Endocrine Tumor
Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
Abnormal PI3K-Akt-mTOR (mammalian target of rapamycin) pathway signaling and autocrine activation of the mTOR pathway, mediated through insulin-like growth factor 1 (IGF1), has been implicated in the proliferation of pNET …
- Trial name
- MetNET1 (NCT02294006)
- Testing
- Everolimus plus Octreotide LAR plus Metformin
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cystic Fibrosis
Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis
The study is defined in 3 stages of in vitro assays : Phase 1 : Secretion of NETs in response to lung disease and their secretion of factors.
- Trial name
- MucoNETs (NCT02564393)
- Where
- France
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Diabetes Mellitus, Kidney Disease
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
This study aims to investigate whether new glucose-lowering medications, such as SGLT2 inhibitors (e.g., Forxiga/Jardiance) and GLP-1 receptor agonists (e.g., Ozempic), can reduce NETosis in diabetic patients, thereby mitigating…
- Trial name
- NETs (NCT06821919)
- Where
- Israel
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Western Galilee Hospital-Nahariya
Advanced/Metastatic Neuroendocrine Tumors
Pazopanib as Single Agent in Advanced NETs
The incidence of new diagnosed patients with NET of the digestive tract including carcinoid and pancreatic islet cells tumors ranges from 2 to 10 per 100,000 in the western Countries (Kulke M, Mayer R.
- Trial name
- NCT01280201
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Pregnancy
IPTp Plus ITNs for Malaria Control in Pregnant Women
We aim to evaluate whether IPT in pregnancy provides any additional benefit to the protection afforded by ITNs.
- Trial name
- NCT00209781
- Testing
- Sulfadoxine-Pyrimethamine (Fansidar), ITNs
- Where
- Mozambique
- Volunteers
- 1,028 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Mediterranean Diet, Neuroendocrine Tumours (NETs)
The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.
Nutritional status in patients with neuroendocrine tumours (NETs), especially of gastroenteropancreatic origin, can be deeply affected by excessive production of gastrointestinal hormones, peptides, and amines, which can lead to…
- Trial name
- NetNutr (NCT03592940)
- Testing
- Mediterranean diet
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University